Department of Chemistry and Chemical Biology, Cornell University , Ithaca, New York.
Cancer Biother Radiopharm. 2018 Oct;33(8):336-348. doi: 10.1089/cbr.2018.2494. Epub 2018 Jun 11.
The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle emissions to destroy tumors. A key factor, however, that may hinder the clinical use of actinium-225 is the poor understanding of its coordination chemistry, which creates challenges for the development of suitable chelation strategies for this ion. In this article, we provide an overview of the known chemistry of actinium and a summary of the chelating agents that have been explored for use in actinium-225-based TAT. This overview provides a starting point for researchers in the field of TAT to gain an understanding of this valuable therapeutic radionuclide.
发射 α 粒子的放射性核素锕-225 具有在靶向 α 治疗 (TAT) 中应用的有前景的核特性,这是一种利用 α 粒子发射来破坏肿瘤的治疗策略。然而,可能阻碍锕-225 临床应用的一个关键因素是对其配位化学的了解不足,这为开发适合该离子的螯合策略带来了挑战。在本文中,我们提供了对已知锕化学的概述,并总结了已探索用于基于锕-225 的 TAT 的螯合剂。该概述为 TAT 领域的研究人员提供了一个起点,以了解这种有价值的治疗性放射性核素。